Internal Medicine, Endocrinology, Diabetes, & Metabolism · Collegeville, PA
NPI
1932385408
Since 2008
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
3
Medicare group memberships
Hospitals
5
Hospital affiliations
599 Arcola Rd
Collegeville, PA, 19426
Phone (610) 649-1922
Groups this clinician bills Medicare through
Medicare paid, 2024
$160K
2,641 services
Medicare patients, 2024
774
Average age 72
Drug cost, 2024
$3.7M
10,103 prescriptions
Company payments, 2025
$939
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Christopher P Bruno was code 99214 (office e&m - established), 1,105 times for 659 patients. In total Christopher P Bruno billed 2,641 services in 28 codes, and Medicare paid $160K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-10-03.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 1,105 | 659 | $98.07 | $108K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 810 | 570 | $12.78 | $10K |
| 95251 Test - Miscellaneous | Office | 258 | 127 | $28.46 | $7,342 |
| G0008 Administration of influenza virus vaccine | Office | 94 | 93 | $33.29 | $3,129 |
| 90662 Vaccine Product | Office | 89 | 88 | $81.38 | $7,242 |
| 99213 Office E&M - Established | Office | 77 | 76 | $55.56 | $4,278 |
| 99215 Office E&M - Established | Office | 73 | 57 | $146.86 | $11K |
| 99204 Office E&M - New | Office | 20 | 20 | $113.58 | $2,272 |
By year: 2022 $164K for 2,177 services; 2023 $158K for 2,110 services; 2024 $160K for 2,641 services.
Medicare prescription drug claims, 2024
In 2024, the drug Christopher P Bruno prescribed most often to Medicare patients was Ozempic (Semaglutide), with 745 prescriptions and refills. In total Christopher P Bruno wrote 10,103 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 745 | 1,129 | 133 | $1.0M |
| Levothyroxine Sodium Generic | 709 | 1,901 | 191 | $6,528 |
| Metformin Hcl Generic | 632 | 1,758 | 183 | $6,425 |
| Synthroid Levothyroxine Sodium | 522 | 1,313 | 130 | $50K |
| Glimepiride Generic | 391 | 1,091 | 108 | $4,370 |
| Metformin Hcl Er Metformin Hcl | 379 | 1,013 | 108 | $5,303 |
| Jardiance Empagliflozin | 374 | 660 | 84 | $373K |
| Tresiba Flextouch U-100 Insulin Degludec | 314 | 752 | 91 | $283K |
| Farxiga Dapagliflozin Propanediol | 306 | 602 | 70 | $326K |
| Novolog Flexpen Insulin Aspart | 283 | 514 | 85 | $82K |
| Glipizide Generic | 245 | 656 | 69 | $2,521 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 234 | 605 | 71 | $38K |
| Januvia Sitagliptin Phosphate | 226 | 457 | 51 | $250K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 223 | 485 | 73 | $26K |
| Rosuvastatin Calcium Generic | 220 | 582 | 65 | $2,457 |
Brand drugs: 4,594 claims; generic drugs: 4,828 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Christopher P Bruno $939 ($939 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbott Laboratories with $232.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 2 | $232 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 5 | $98.41 |
| Medtronic, Inc. MDT | 3 | $82.17 |
| Novo Nordisk Inc NVO | 3 | $76.15 |
| Abbvie Inc. ABBV | 3 | $67.84 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $61.19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $56.88 |
| IBSA Pharma Inc. | 2 | $48.54 |
| Amgen Inc. AMGN | 2 | $39.47 |
| Mannkind Corporation MNKD | 2 | $28.52 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.